Last month, biologist Kevin Eggan took to the stage at the Harvard Stem Cell Institute and startled everyone with his announcement: More than a year after their proposal to start human therapeutic-cloning research had been approved, Eggan and his team were still at square one. Despite spending more than $100,000 on advertising, they had yet...